Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H. Moskowitz, John Sweetenham, Jan Walewski et al.|Blood|2018Cited by 250
Animal movements in fire‐prone landscapesDale G. Nimmo, Andrew F. Bennett, Sarah C. Avitabile et al.|Biological reviews/Biological reviews of the Cambridge Philosophical Society|2018Cited by 184
Sulfurization of Dissolved Organic Matter Increases Hg–Sulfide–Dissolved Organic Matter Bioavailability to a Hg-Methylating BacteriumAndrew M. Graham, Cynthia C. Gilmour, Keaton T. Cameron-Burr et al.|Environmental Science & Technology|2017Cited by 92
Abstract 11395: Small Molecule Antidote for AnticoagulantsBryan Laulicht, Solomon S. Steiner, Christopher Baker et al.|Circulation|2012Cited by 43
MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancerStephen Sener, Julie E. Lang, Rachel E. Sargent et al.|Journal of Surgical Oncology|2019Cited by 32